Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:MRX

Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Medicis Pharmaceutical logo

About Medicis Pharmaceutical Stock (NYSE:MRX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$32.54
$33.33
50-Day Range
N/A
52-Week Range
$18.13
$40.05
Volume
415,945 shs
Average Volume
381,702 shs
Market Capitalization
$2.69 billion
P/E Ratio
N/A
Dividend Yield
1.46%
Price Target
$35.00
Consensus Rating
Moderate Buy

Company Overview

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

Remove Ads

Medicis Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

MRX MarketRank™: 

Medicis Pharmaceutical scored higher than 14% of companies evaluated by MarketBeat, and ranked 909th out of 939 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medicis Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Medicis Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Medicis Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.94 to $2.93 per share.

  • Short Interest

    There is no current short interest data available for MRX.
  • Dividend Yield

    Medicis Pharmaceutical pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Medicis Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.11% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Medicis Pharmaceutical's dividend.
  • Short Interest

    There is no current short interest data available for MRX.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Medicis Pharmaceutical this week, compared to 0 articles on an average week.
  • Search Interest

    Only 7 people have searched for MRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Medicis Pharmaceutical to their MarketBeat watchlist in the last 30 days.
Receive MRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

MRX Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Marex Group plc Announces Third Quarter 2024 Results
Marex Group plc Announces Pricing of the Public Offering
See More Headlines

MRX Stock Analysis - Frequently Asked Questions

Medicis Pharmaceutical Corp (NYSE:MRX) posted its earnings results on Thursday, March, 6th. The healthcare company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.12.

Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
3/06/2025
Record date for 3/31 Dividend
3/17/2025
Ex-Dividend for 3/31 Dividend
3/17/2025
Dividend Payable
3/31/2025
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Finance
Industry
Security & commodity brokers, dealers, exchanges & services
Sub-Industry
N/A
Current Symbol
NYSE:MRX
Fax
N/A
Employees
2,074
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$43.00
Low Stock Price Target
$24.00
Potential Upside/Downside
-8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
67,627,000
Market Cap
$2.69 billion
Optionable
Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NYSE:MRX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners